Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-5c6d5d7d68-ckgrl Total loading time: 0 Render date: 2024-08-10T02:54:31.539Z Has data issue: false hasContentIssue false

17 - HIV postexposure prophylaxis for pediatric patients

Published online by Cambridge University Press:  23 December 2009

By
Peter L. Havens  and
Kenneth L. Dominguez
Edited by
Steven L. Zeichner  and
Jennifer S. Read
Peter L. Havens
Affiliation:
Medical College of Wisconsin and MACC Fund Research Center, Milwaukee, WI
Kenneth L. Dominguez
Affiliation:
Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA
Steven L. Zeichner
Affiliation:
National Cancer Institute, Bethesda, Maryland
Jennifer S. Read
Affiliation:
National Institutes of Health, Bethesda, Maryland
Get access

Summary

Introduction

This chapter addresses HIV postexposure prophylaxis (PEP) in the following situations: injury from discarded needles, bite wounds, sexual exposure, and inadvertent exposure to human milk from an HIV-infected woman. In each setting, the risk of HIV transmission is directly related to the probability that the exposure source has HIV infection and that transmission of a sufficient amount of infectious virus occurred in a manner that could result in infection in the recipient. Because no studies have directly measured the effectiveness of PEP in decreasing the risk of HIV transmission in non-occupational settings or after mucosal exposure, the potential benefit of PEP in modifying transmission risk is extrapolated from data regarding HIV pathogenesis in animals, from information about PEP for needle-stick injuries in occupational settings, and from studies of mother-to-child transmission (MTCT) of HIV. Guidelines for prophylaxis after exposure to HIV in occupational and non-occupational settings have been published by the US Public Health Service (USPHS) [1–3], the American Academy of Pediatrics [4], the NY State Department of Health [5], and others [6].

Factors affecting HIV transmission risk after potential exposure

Type of source material

Not all body fluids from persons with HIV infection are equally infectious (Table 17.1). Blood and fluids contaminated with blood from persons with HIV infection are assumed to contain HIV and are associated with the highest risk of HIV transmission.

Type
Chapter
Information
Handbook of Pediatric HIV Care , pp. 450 - 470
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Morb. Mortal. Wkly Rep. 1998;47(relative risk-7):1–33.
Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to hepatitis virus B, HCV, and human immunodeficiency virus and recommendations for postexposure prophylaxis. Marb. Mortal. Wkly. Rep. 2001;50(relative risk-11):1–52.
Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other non-occupational exposure to human immunodeficiency virus in the United States: recommendations from the U. S. Department of Health and Human Services. 2005;54 (relative risk-2): 1–20.
Havens, P. L. and the Committee on Pediatric acquired immune deficiency syndrome, American Academy of Pediatrics. Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 2003, 111:1475–1489.CrossRefGoogle Scholar
New York State Department of Health acquired immune deficiency syndrome Institute. human immunodeficiency virus Postexposure prophylaxis for children beyond the neonatal period: Tables and recommendations. 2002. accessed 5-7-03. http://hivguidelines.org/public_html/center/clinical-guidelines/ped_adolescent_hiv_guidelines/html/peds_pep/pdf/peds_pep_tables.pdf.
Merchant, R. C., Keshavarz, R.Human immunodeficiency virus postexposure prophylaxis for adolescents and children. Pediatrics 2001;108:e38. http://www.pediatrics.org/cgi/content/full/108/2/e38.CrossRefGoogle ScholarPubMed
Cardo, D. M., Culver, D. H., Ciesielski, C. A.et al.A case-control study of human immunodeficiency virus seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needle stick Surveillance Group. N. Engl. J. Med. 1997;337:1485–1490.CrossRefGoogle ScholarPubMed
Gray, R. H., Wawer, M. J., Brookmeyer, R.et al.Probability of human immunodeficiency virus-1 transmission per coital act in monogamous, heterosexual, human immunodeficiency virus-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149–1153.CrossRefGoogle ScholarPubMed
Mofenson, L. M., Lambert, J. S., Stiehm, E. R.et al.Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric acquired immune deficiency syndrome Clinical Trials Group Study 185 Team. N. Engl. J. Med. 1999;341:385–393.CrossRefGoogle ScholarPubMed
Garcia, P. M., Kalish, L. A., Pitt, J.et al.Maternal levels of plasma human immunodeficiency virus type 1 ribonucleic acid and the risk of perinatal transmission. Women and Infants Transmission Study Group. N. Engl. J. Med. 1999;341:394–402.CrossRefGoogle ScholarPubMed
Ioannidis, J. P. A., Abrams, E. J., Ammann, A.et al.Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with ribonucleic acid virus loads <1000 copies/ml. J. Infect. Dis. 2001;183(4): 539–545.CrossRefGoogle ScholarPubMed
Hart, C. E., Lennox, J. L., Pratt-Palmore, M.et al.Correlation of human immunodeficiency virus type 1 ribonucleic acid levels in blood and the female genital tract. J. Infect. Dis. 1999;179:871–882.CrossRefGoogle ScholarPubMed
Rich, J. D., Dickinson, B. P., Carney, J. M., Fisher, A., Heimer, R.Detection of human immunodeficiency virus-1 nucleic acid and human immunodeficiency virus-1 antibodies in needles and syringes used for non-intravenous injection. acquired immune deficiency syndrome 1998;12:2345–2350.Google ScholarPubMed
Resnick, L., Veren, K., Salahuddin, S. Z., Tondreau, S., Markham, P. D.Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. J. Am. Med. Assoc. 1986;255:1887–1891.CrossRefGoogle ScholarPubMed
Abdala, N., Stephens, P. C., Griffith, B. P., Heimer, R.Survival of human immunodeficiency virus-1 in syringes. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1999;20:73–80.CrossRefGoogle ScholarPubMed
Zamora, A. B., Rivera, M. O., Garcia-Algar, O., Buqueras, Cayla J., Combelles, Vall O., Garcia-Saiz, A.Detection of infectious human immunodeficiency type 1 virus in discarded syringes of intravenous drug users. Pediatr. Infect. Dis. J. 1998;17:655–657.CrossRefGoogle ScholarPubMed
Walsh, S. S., Pierce, A. M., Hart, C. A.Drug abuse: a new problem. Br. Med. J. (Clin. Res. Ed.). 1987;295:526–527.CrossRefGoogle ScholarPubMed
Montella, F., DiSora, F., Recchia, O.Can human immunodeficiency virus-1 infection be transmitted by a “discarded” syringe?J. Acquir. Immune Defic. Syndr. 1992;5:1274–1275.CrossRefGoogle ScholarPubMed
Donegan, E., Stuart, M., Niland, J. C.et al.Infection with human immunodeficiency virus type 1 (human immunodeficiency virus-1) among recipients of antibody-positive blood donations. Ann. Intern. Med. 1990;113:733–739.CrossRefGoogle ScholarPubMed
The Working Group on Mother-to-Child Transmission of human immunodeficiency virus. Rates of mother-to-child transmission of human immunodeficiency virus-1 in Africa, America, and Europe: results from 13 perinatal studies. The Working Group on Mother-to-Child Transmission of human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995;8:506–510.CrossRef
Kaplan, E. H., Heimer, R.A model-based estimate of human immunodeficiency virus infectivity via needle sharing. J. Acquir. Immune Defic. Syndr. 1992;5:1116–1118.Google ScholarPubMed
Tokars, J. I., Marcus, R., Culver, D. H.et al.Surveillance of human immunodeficiency virus infection and zidovudine use among health care workers after occupational exposure to human immunodeficiency virus-infected blood. The Centers for Disease Control and Prevention Needle stick Surveillance Group. Ann. Intern. Med. 1993;118:913–919.CrossRefGoogle Scholar
Bell, D. M.Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am. J. Med. 1997;102:9–15.CrossRefGoogle ScholarPubMed
Katz, M. H., Gerberding, J. L.The care of persons with recent sexual exposure to human immunodeficiency virus. Ann. Intern. Med. 1998;128:306–312.CrossRefGoogle Scholar
Mastro, T. D., de Vincenzi, I. Probabilities of sexual human immunodeficiency virus-1 transmission. acquired immune deficiency syndrome 1996;10:S75-S82.Google Scholar
DeGruttola, V., Seage, G. R. III, Mayer, K. H., Horsburgh, C. R. Jr.Infectiousness of human immunodeficiency virus between male homosexual partners. J. Clin. Epidemiol. 1989;42:849–856.CrossRefGoogle ScholarPubMed
Wiley, J. A., Herschkorn, S. J., Padian, N. S.Heterogeneity in the probability of human immunodeficiency virus transmission per sexual contact: the case of male-to-female transmission in penile–vaginal intercourse. Stat. Med. 1989;8:93–102.CrossRefGoogle ScholarPubMed
Peterman, T. A., Stoneburner, R. L., Allen, J. R., Jaffe, H. W., Curran, J. W.Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. J. Am. Med. Assoc. 1988;259:55–58.CrossRefGoogle ScholarPubMed
Downs, A. M., DeVincenzi, I.Probability of heterosexual transmission of human immunodeficiency virus: relationship to the number of unprotected sexual contacts. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996;11:388–395.CrossRefGoogle ScholarPubMed
Lane, H. C., Holmberg, S. D., Jaffe, H. W.human immunodeficiency virus seroconversion and oral intercourse. Am. J. Publ. Hlth. 1991;81:658.CrossRefGoogle ScholarPubMed
Keet, I. P., Lent, Albrecht N., Sandfort, T. G., Coutinho, R. A., Griensven, G. J.Orogenital sex and the transmission of human immunodeficiency virus among homosexual men. acquired immune deficiency syndrome 1992;6:223–226.Google ScholarPubMed
Goldberg, D. J., Green, S. T., Kennedy, D. H., Emslie, J. A., Black, J. D.human immunodeficiency virus and orogenital transmission [lett]. Lancet 1988;2:1363.CrossRefGoogle Scholar
Berrey, M. M., Shea, T.Oral sex and human immunodeficiency virus transmission [lett]. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997;14:475.Google Scholar
Lifson, A. R., O'Malley, P. M., Hessol, N. A., Buchbinder, S. P., Cannon, L., Rutherford, G. W.human immunodeficiency virus seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counseling concerning safe sexual practices. Am. J. Publ. Hlth. 1990;80:1509–1511.CrossRefGoogle ScholarPubMed
DeGruttola, V., Mayer, K. H.Human immunodeficiency virus and oral intercourse [lett]. Ann. Intern. Med. 1987;107:428–429.Google Scholar
Royce, R. A., Sena, A., Cates, W. Jr, Cohen, M. S.Sexual transmission of human immunodeficiency virus. N. Engl. J. Med. 1997;336:1072–1078.CrossRefGoogle Scholar
Richardson, B. A., John-Stewart, G., Hughes, J. P.et al.Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J. Infect. Dis. 2003;187:736–740.CrossRefGoogle ScholarPubMed
Dominguez, K. L.Management of human immunodeficiency virus-infected children in the home and institutional settings. Care of children and infections control in schools, day care, hospital settings, home, foster care, and adoption. Pediatr. Clin. North. Am. 2000; 47:203–239.CrossRefGoogle Scholar
Anonymous. Transmission of human immunodeficiency virus by human bite. Lancet 1987;2:522.
Vidmar, L., Poljak, M., Tomazic, J., Seme, K., Klavs, I.Transmission of human immunodeficiency virus-1 by human bite [lett]. Lancet. 1996;347:1762.CrossRefGoogle Scholar
Richman, K. M., Rickman, L. S.The potential for transmission of human immunodeficiency virus through human bites. J. Acquir. Immune Defic. Syndr. 1993;6:402–406.Google ScholarPubMed
Abel, S., Cesaire, R., Cales-Quist, D., Bera, O., Sobesky, G., Cabie, A.Occupational transmission of human immunodeficiency virus and hepatitis C virus after a punch. Clin. Infect. Dis. 2000;31:1494–1495.CrossRefGoogle Scholar
Yeh, C. K., Handelman, B., Fox, P. C., Baum, B. J.Further studies of salivary inhibition of human immunodeficiency virus-1 infectivity. J. Acquir. Immune Defic. Syndr. 1992;5:898–903.Google Scholar
Centers for Disease Control and Prevention. Transmission of human immunodeficiency virus possibly associated with exposure of mucous membrane to contaminated blood. Morb. Mortal. Wkly Rep. 1997;46:620–623.
Henderson, D. K., Fahey, B. J., Willy, M.et al.Risk for occupational transmission of human immunodeficiency virus type 1 (human immunodeficiency virus-1) associated with clinical exposures. A prospective evaluation. Ann. Intern. Med. 1990;113:740–746.CrossRefGoogle ScholarPubMed
Ippolito, G., Puro, V., Carli, G.The risk of occupational human immunodeficiency virus infection in health care workers. The Italian Study Group on Occupational Risk of human immunodeficiency virus Infection. Arch. Intern. Med. 1993;153:1451–1458.CrossRefGoogle Scholar
Little, S. J., McLean, A. R., Spina, C. A., Richman, D. D., Havlir, D. V.Viral dynamics of acute human immunodeficiency virus-1 infection. J. Exp. Med. 1999;190:841–850.CrossRefGoogle Scholar
Katzenstein, T. L., Dickmeiss, E., Aladdin, H.et al.Failure to develop human immunodeficiency virus infection after receipt of human immunodeficiency virus-contaminated blood and postexposure prophylaxis. Ann. Int. Med. 2000;133:31–34.CrossRefGoogle Scholar
Rompay, K. K., Marthas, M. L., Lifson, J. D.et al.Administration of 9-[2-(phosphonomethoxy)propyl]adenine (9-[2-(R)-(phosphonylmethoxy)propyl] adenine) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. acquired immune deficiency syndrome Res. Hum. Retrovirus. 1998;14:761–773.Google Scholar
Tavares, L., Roneker, C., Johnston, K., Lehrman, S. N., Noronha, F.3′-Azido-3'deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of acquired immune deficiency syndrome. Cancer Res. 1987;47:3190–3194.Google Scholar
Shih, C. C., Kaneshima, H., Rabin, L.et al.Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J. Infect. Dis. 1991;163:625–627.CrossRefGoogle Scholar
Rompay, K. K., Otsyula, M. G., Marthas, M. L., Miller, C. J., McChesney, M. B., Pedersen, N. C.Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of acquired immune deficiency syndrome. Antimicrob. Agents Chemother. 1995;39:125–131.CrossRefGoogle Scholar
Bottiger, D., Johansson, N. G., Samuelsson, B.et al.Prevention of simian immunodeficiency virus, simian immunodeficiency virussm, or human immunodeficiency virus-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. acquired immune deficiency syndrome 1997;11:157–162.Google ScholarPubMed
Black, R. J.Animal studies of prophylaxis. Am. J. Med. 1997;102:39–44.CrossRefGoogle ScholarPubMed
Sinet, M., Desforges, B., Launay, O., Colin, J. N., Pocidalo, J. J.Factors influencing zidovudine efficacy when administered at early stages of Friend virus infection in mice. Antiviral Res. 1991;16:163–171.CrossRefGoogle ScholarPubMed
Tsai, C. C., Emau, P., Follis, K. E.et al.Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus simian immunodeficiency virusmne infection depends critically on timing of initiation and duration of treatment. J. Virol. 1998;72:4265–4273.Google ScholarPubMed
Otten, R. A., Smith, D. K., Adams, D. R.et al.Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J. Virol. 2000;74:9771–9775.CrossRefGoogle Scholar
Martin, L. N., Murphey-Corb, M., Soike, K. F., Davison-Fairburn, B., Baskin, G. B.Effects of initiation of 3'-azido, 3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J. Infect. Dis. 1993;168:825–835.CrossRefGoogle ScholarPubMed
Fazely, F., Haseltine, W. A., Rodger, R. F., Ruprecht, R. M., Postexposure chemoprophylaxis with zidovudine (also known as zidovudine (also known as ZDV)) or zidovudine (also known as zidovudine (also known as ZDV)) combined with interferon-alpha: failure after inoculating rhesus monkeys with a high dose of simian immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 1991;4:1093–1097.Google Scholar
Ruprecht, R. M., Bronson, R.Chemoprevention of retroviral infection: success is determined by virus inoculum strength and cellular immunity. deoxyribonucleic acid Cell Biol. 1994;13:59–66.Google ScholarPubMed
Niu, M. T., Stein, D. S., Schnittman, S. M.Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J. Infect. Dis. 1993;168:1490–1501.CrossRefGoogle ScholarPubMed
Schacker, T., Collier, A. C., Hughes, J., Shea, T., Corey, L.Clinical and epidemiologic features of primary human immunodeficiency virus infection. Ann Intern Med. 1996;125:257–264.CrossRefGoogle Scholar
Ruprecht, R. M., Chou, T. C., Chipty, F.et al.Interferon-alpha and 3′-azido-3′-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. J. Acquir. Immune Defic. Syndr. 1990;3:591–600.Google ScholarPubMed
Mathes, L. E., Polas, P. J., Hayes, K. A., Swenson, C. L., Johnson, S., Kociba, G. J.Pre- and postexposure chemoprophylaxis: evidence that 3′-azido-3′-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob. Agents Chemother. 1992;36:2715–2721.CrossRefGoogle ScholarPubMed
Grob, P. M., Cao, Y., Muchmore, E.et al.Prophylaxis against human immunodeficiency virus-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nature Med. 1997;3:665–670.CrossRefGoogle ScholarPubMed
Clerici, M., Giorgi, J. V., Chou, C. C.et al.Cell-mediated immune response to human immunodeficiency virus (human immunodeficiency virus) type 1 in seronegative homosexual men with recent sexual exposure to human immunodeficiency virus-1. J. Infect. Dis. 1992;165:1012–1019.CrossRefGoogle Scholar
Pinto, L. A., Sullivan, J., Berzofsky, J. A.et al.ENV-specific cytotoxic T lymphocyte response in human immunodeficiency virus seronegative health care workers occupationally exposed to human immunodeficiency virus-contaminated body fluids. J. Clin. Invest. 1995;96:867–876.CrossRefGoogle Scholar
D'Amico, R., Pinto, L. A., Meyer, P.et al.Effect of zidovudine postexposure prophylaxis on the development of human immunodeficiency virus-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus-exposed healthcare workers. Infect. Control Hosp. Epidemiol. 1999;20:428–430.CrossRefGoogle Scholar
Connor, E. M., Sperling, R. S., Gelber, R.et al.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric acquired immune deficiency syndrome Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 1994;331:1173–1180.CrossRefGoogle ScholarPubMed
Guay, L. A., Musoke, P., Fleming, T.et al.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of human immunodeficiency virus-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795–802.CrossRefGoogle ScholarPubMed
Cooper, E. R., Charurat, M., Mofenson, L.et al.Combination antiretroviral strategies for the treatment of pregnant human immunodeficiency virus-1-infected women and prevention of perinatal human immunodeficiency virus-1 transmission. J. Acquir. Immune Defic. Syndr. 2002;29:484–494.CrossRefGoogle Scholar
Wade, N. A., Birkhead, G. S., Warren, B. L.et al.Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N. Engl. J. Med. 1998;339:1409–1414.CrossRefGoogle ScholarPubMed
Wade, N. A., Birkhead, G. S., French P. T. Short courses of zidovudine and perinatal transmission of human immunodeficiency virus [response to letters]. N. Engl. J. Med. 1999;340:1043–1043.Google Scholar
Ippolito, G., Puro, V., Heptonstall, J., Jagger, J., Carli, G., Petrosillo, N.Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Clin. Infect. Dis. 1999;28:365–383.CrossRefGoogle ScholarPubMed
Lange, J. M., Boucher, C. A., Hollak, C. E.et al.Failure of zidovudine prophylaxis after accidental exposure to human immunodeficiency virus-1. N. Engl. J. Med. 1990;322:1375–1377.CrossRefGoogle Scholar
Jochimsen, E. M., Luo, C. C., Beltrami, J. F., Respess, R. A., Schable, C. A., Cardo, D. M.Investigations of possible failures of postexposure prophylaxis following occupational exposures to human immunodeficiency virus. Arch. Intern. Med. 1999;159:2361–2363.CrossRefGoogle ScholarPubMed
Erice, A., Mayers, D. L., Strike, D. G.et al.Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N. Engl. J. Med. 1993;328:1163–1165.CrossRefGoogle ScholarPubMed
Kahn, J. O., Martin, J. N., Roland, M. E.et al.Feasibility of postexposure prophylaxis (postexposure prophylaxis) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco postexposure prophylaxis Study. J. Infect. Dis. 2001;183:707–714.CrossRefGoogle ScholarPubMed
Kunches, L. M., Meehan, T. M., Boutwell, R. C., McGuire, J. F.Survey of nonoccupational human immunodeficiency virus postexposure prophylaxis in hospital emergency departments. J. Acquir. Immune Defic. Syndr. 2001;26:263–265.CrossRefGoogle ScholarPubMed
Fournier, S., Maillard, A., Molina, J. M.Failure of postexposure prophylaxis after sexual exposure to human immunodeficiency virus. acquired immune deficiency syndrome 2001;15:430.Google Scholar
Waldo, C. R., Stall, R. D., Coates, T. J.Is offering post-exposure prevention for sexual exposures to human immunodeficiency virus related to sexual risk behavior in gay men?acquired immune deficiency syndrome 2000;14:1035–1039.Google ScholarPubMed
Braitstein, P., Chan, K., Beardsell, A.et al.How much is it worth? Actual versus expected costs of a population-based post-exposure prophylaxis program [Abstr 270P]. Can. J. Infect. Dis. 2001;12(Suppl B):45B–46B.Google Scholar
Braitstein, P., Chan, K., Beardsell, A.et al.Side effects associated with post-exposure prophylaxis in a population-based setting [Abstr 271P]. Can. J. Infect. Dis. 2001;12(Suppl B):46B.Google Scholar
Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after human immunodeficiency virus exposures – worldwide, 1997–2000. Morb. Mortal. Wkly Rep. 2001;49:1153–1156.
Lindegren, M. L., Hanson, I. C., Hammett, T. A., Beil, J., Fleming, P. L., Ward, J. W.Sexual abuse of children: intersection with the human immunodeficiency virus epidemic. Pediatrics. 1998;102(4). Available at: http://www.pediatrics.org/cgi/content/full/102/4/e46CrossRefGoogle Scholar
Gostin, L. O., Lazzarini, Z., Alexander, D., Brandt, A. M., Mayer, K. H., Silverman, D. C.human immunodeficiency virus testing, counseling, and prophylaxis after sexual assault. J. Am. Med. Assoc. 1994;271:1436–1444.CrossRefGoogle ScholarPubMed
Bamberger, J. D., Waldo, C. R., Gerberding, J. L., Katz, M. H.Postexposure prophylaxis for human immunodeficiency virus (human immunodeficiency virus) infection following sexual assault. Am. J. Med. 1999;106:323–326.CrossRefGoogle ScholarPubMed
Katz, M. H., Gerberding, J. L.Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N. Engl. J. Med. 1997;336:1097–1100.CrossRefGoogle ScholarPubMed
Evans, B., Darbyshire, J., Cartledge, J.Should preventive antiretroviral treatment be offered following sexual exposure to human immunodeficiency virus? Not yet!Sex Transm. Infect. 1998;74:146–148.CrossRefGoogle Scholar
Lurie, P., Miller, S., Hecht, F., Chesney, M., Lo, B.Postexposure prophylaxis after nonoccupational human immunodeficiency virus exposure: clinical, ethical, and policy considerations. J. Am. Med. Assoc. 1998;280:1769–1773.CrossRefGoogle ScholarPubMed
Gwinn, M., Wortley, P. M.Epidemiology of human immunodeficiency virus infection in women and newborns. Clin. Obstet. Gynecol. 1996;39:292–304.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Revised recommendations for human immunodeficiency virus screening of pregnant women. Morb. Mortal. Wkly Rep. 2001;50(relative risk-19):63–85.
Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morb. Mortal. Wkly Rep. 1994;43(relative risk-11):1–20.
Ippolito, G., Puro, V.Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis. Am. J. Med. 1997;102:58–62.CrossRefGoogle ScholarPubMed
Henry, K., Acosta, E. P., Jochimsen, E.Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis [lett]. Ann. Intern. Med. 1996;124:855.CrossRefGoogle Scholar
Forseter, G., Joline, C., Wormser, G. P.Tolerability, safety, and acceptability of zidovudine prophylaxis in health care workers. Arch. Intern. Med. 1994;154:2745–2749.CrossRefGoogle ScholarPubMed
Sepkowitz, K. A., Rivera, P., Louther, J., Lim, S., Pryor, B.Postexposure prophylaxis for human immunodeficiency virus: frequency of initiation and completion of newly recommended regimen. Infect. Control Hosp. Epidemiol. 1998;19:506–508.CrossRefGoogle ScholarPubMed
Babl, F. E., Cooper, E. R., Damon, B., Louie, T., Kharasch, S., Harris, J. A.human immunodeficiency virus postexposure prophylaxis for children and adolescents. Am. J. Emerg. Med. 2000;18:282–287.CrossRefGoogle ScholarPubMed
Wiebe, E. R., Comay, S. E., McGregor, M., Ducceschi, S.Offering human immunodeficiency virus prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service. CMAJ 2000;162:641–645.Google Scholar
Myles, J. E., Hirozawa, A., Katz, M. H., Kimmerling, R., Bamberger, J. D.Postexposure prophylaxis for human immunodeficiency virus after sexual assault. J. Am. Med. Assoc. 2000;284:1516–1518.CrossRefGoogle ScholarPubMed
Benn, P. D., Mercey, D. E., Brink, N., Scott, G., Williams, I. G.Prophylaxis with a nevirapine-containing triple regimen after exposure to human immunodeficiency virus-1. Lancet 2001;357:687–688.CrossRefGoogle Scholar
American Academy of Pediatrics. Red Book 2003: Report of the Committee on Infectious Diseases. Elk Grove Village, interleukin.: American Academy of Pediatrics; 2003.
Busch, M. P., Satten, G. A.Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am. J. Med. 1997;102:117–126.CrossRefGoogle ScholarPubMed
Ciesielski, C. A., Metler, R. P.Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Am. J. Med. 1997;102:115–116.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×